Table 3.
Reported varied worldwide prevalence for β- and γ-HPV types in the male anal canal.
| Study country | Study population | HPV genotyping, technique employed | Studied samples |
β-HPV types |
γ-HPV types |
||
|---|---|---|---|---|---|---|---|
| Overall prevalence | Most common | Overall prevalence | Most common | ||||
| Russia, this study | HIV- MSW | Luminex | 354 | 20.1 | 110, 124, 22 | 10.7 | 95, 132, 50 |
| HIV+ MSW | Luminex | 31 | 74.2 | 22, 12, 38 | 48.4 | 148, 133, 123 | |
| USA (15) | HIV- men | Luminex | 238 | 48.7 | 38, 21, 22 | ||
| Brazil (15) | HIV- men | Luminex | 241 | 48.6 | |||
| Mexico (15) | HIV- men | Luminex | 238 | 65.6 | |||
| Italy (12) | HIV- MSM | Luminex | 602 | 27.2 | 111, 120, 24 | ||
| HIV+ MSM | Luminex | 602 | 28.6 | 111, 120, 38 | |||
| HIV- MSM | Luminex | 597 | 27.9 | 121, 50, 133 | |||
| HIV+ MSM | Luminex | 597 | 33.5 | 121, 108, 132 | |||
| Spain (13) | HIV- MSM | Luminex | 153 | 59.1 | 38, 120 | 57.7 | 133, 121 |
| HIV+ MSM | Luminex | 66 | 65.6 | 12, 107 | 68.2 | 121, 50 | |
| Slovenia (11) | HIV- MSM | HPV Linear Array | 112 | 58.9 | 36, 38, 23, 24 | ||
| HIV+ MSM | HPV Linear Array | 23 | 95.7 | ||||
HIV-: HIV-negative; HIV+: HIV-positive